MKI2MAG-94K
MILLIPLEX® Mouse Kidney Injury Magnetic Bead Panel 2 - Toxicity Multiplex Assay
The analytes available for this multiplex kit are: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN) (for urine samples) or Clusterin, Cystatin C, Lipocalin-2/NGAL, Osteopontin (OPN) (for serum/plasma samples).
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84
Recommended Products
Quality Level
species reactivity
mouse
manufacturer/tradename
Milliplex®
assay range
accuracy: 90-99%
sensitivity: 0.005-0.190 ng/mL
(MinDC+2SD)
standard curve range: 0.005-5 ng/mL
(Lipocalin-2/NGAL)
standard curve range: 0.01-10 ng/mL
(Osteopontin (OPN))
standard curve range: 0.04-40 ng/mL
(EGF)
standard curve range: 0.05-50 ng/mL
(Cystatin C)
standard curve range: 0.2-250 ng/mL
(Clusterin)
technique(s)
multiplexing: suitable
detection method
fluorometric (Luminex xMAP)
shipped in
wet ice
General description
Maintenance of physiological balance in the body is attributed in part to normal kidney function. An altered kidney function due to injury, drug toxicity or kidney failure may be life threatening. There are multiple risk factors for kidney injury including age, hypertension, diabetes mellitus, heart failure and liver failure. On the other hand, drug induced damage to the kidney results from drug excretion. Traditional markers for assessing renal toxicity, such as blood urea nitrogen (BUN) and serum creatinine, are insensitive and non-specific. Although both are direct measurements of renal function, increases in serum concentrations of these biomarkers occur only after substantial renal injury. Specificity and earlier detection of kidney injury is vital. For improved detection of acute nephrotoxicity, a panel of novel urinary kidney biomarkers has been identified and validated for preclinical studies in relevant animal species. We provide valuable research assays to investigate multiple biomarkers of kidney injury in mouse urine samples using the Luminex® xMAP® instrument platform.
The MILLIPLEX® Mouse Kidney Injury Bead Panel 2 contains all the components necessary to measure the following five biomarkers in any combination using Luminex® xMAP® technology: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN). The kit uses a 96-well format, contains a lyophilized standard cocktail, two quality controls and can measure up to 38 urine samples in duplicate.
Panel Type: Toxicity
The MILLIPLEX® Mouse Kidney Injury Bead Panel 2 contains all the components necessary to measure the following five biomarkers in any combination using Luminex® xMAP® technology: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN). The kit uses a 96-well format, contains a lyophilized standard cocktail, two quality controls and can measure up to 38 urine samples in duplicate.
Panel Type: Toxicity
Specificity
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes within a panel.
Application
- Analytes: Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN)
- Recommended Sample type: urine
- Recommended Sample dilution: 1:1,000
- Assay Run Time: overnight
- Research Category: Toxicity
Features and Benefits
Design your multiplex kit by choosing available analytes within this panel.
Packaging
Everything you need in a single kit.
Storage and Stability
Recommended storage for kit components is 2 - 8°C.
Other Notes
Please contact Technical Service for linearity of dilution.
Sensitivity: Please see kit protocol for individual assay sensitivities.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
Target Organs
Respiratory Tract
Storage Class Code
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lucía Echevarría et al.
Methods in molecular biology (Clifton, N.J.), 2434, 371-384 (2022-02-26)
Antisense oligonucleotides (ASO) therapeutics hold great promise for the treatment of numerous diseases, and several ASO drugs have now reached market approval, confirming the potential of this approach. However, some candidates have also failed, due to limited biodistribution/uptake and poor
Karima Relizani et al.
Molecular therapy. Nucleic acids, 8, 144-157 (2017-09-18)
Antisense oligonucleotides (AONs) hold promise for therapeutic splice-switching correction in many genetic diseases. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake and sufficient therapeutic efficacy is still difficult to
Karima Relizani et al.
Nucleic acids research, 50(1), 17-34 (2021-12-12)
Tricyclo-DNA (tcDNA) is a conformationally constrained oligonucleotide analog that has demonstrated great therapeutic potential as antisense oligonucleotide (ASO) for several diseases. Like most ASOs in clinical development, tcDNA were modified with phosphorothioate (PS) backbone for therapeutic purposes in order to
Philippine Aupy et al.
Molecular therapy. Nucleic acids, 19, 371-383 (2019-12-28)
Tricyclo-DNA (tcDNA) antisense oligonucleotides (ASOs) hold promise for therapeutic splice-switching applications and the treatment of Duchenne muscular dystrophy (DMD) in particular. We have previously reported the therapeutic potential of tcDNA-ASO in mouse models of DMD, highlighting their unique pharmaceutical properties
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service